Leerink Partnrs Has Bullish Estimate for Nkarta Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for Nkarta to ($0.37), slightly improving from a previous estimate of ($0.38).
• The consensus target price for Nkarta is currently $13.60, with a majority of analysts rating the stock as a "buy."
• Nkara's stock opened at $2.20, reflecting fluctuations within a fifty-two week range of $1.31 to $6.63.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Investment analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Nkarta in a report released on Wednesday, August 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.71) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($1.04) EPS.

Other equities research analysts also recently issued research reports about the company. William Blair reiterated a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Stifel Nicolaus decreased their price target on Nkarta from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price target on shares of Nkarta in a research report on Wednesday, August 13th. Mizuho decreased their price target on Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. Finally, Wall Street Zen upgraded Nkarta from a "sell" rating to a "hold" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $13.60.

Nkarta Price Performance

Shares of NASDAQ:NKTX traded down $0.05 on Friday, reaching $2.30. 536,847 shares of the company traded hands, compared to its average volume of 954,760. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $6.63. The company's 50 day moving average is $1.94 and its 200-day moving average is $1.88. The stock has a market capitalization of $163.37 million, a PE ratio of -1.55 and a beta of 0.72.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.06.

Hedge Funds Weigh In On Nkarta

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in shares of Nkarta during the 4th quarter worth about $30,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Nkarta during the 1st quarter worth about $32,000. ProShare Advisors LLC purchased a new stake in shares of Nkarta during the 4th quarter worth about $45,000. Savant Capital LLC purchased a new stake in shares of Nkarta during the 2nd quarter worth about $36,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Nkarta by 41.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after purchasing an additional 7,030 shares in the last quarter. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.